Compare · head to head
Medpaces vs Taysha Gene Therapies
Medpaces ranks higher overall — 360 rank 96 vs 21.
Medpaces leads on Value (54 vs 32), Quality (83 vs 33), Growth (64 vs 50) and Safety (63 vs 43). Taysha Gene Therapies leads on Sentiment (58 vs 43).
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Life Sciences Tools & Services | Biotechnology |
| Size | Large | Small |
| ISIN | US58506Q1094 | US8776191061 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 96 | 21 |
| Value | 54 | 32 |
| Quality | 83 | 33 |
| Growth | 64 | 50 |
| Safety | 63 | 43 |
| Sentiment | 43 | 58 |
| Quality details | ||
| Profitability | 95 | 31 |
| Cash Truth | 71 | 35 |
Medpaces vs TriSalus Life SciencesMedpaces vs CertaraMedpaces vs ArdelyxMedpaces vs Dianthus TherapeuticsAdd a third stock →
Full analyses: Medpaces · Taysha Gene Therapies
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100